Rebates, what rebates? Understanding pharmacy rebates for J-Code drugs

Pharmacy rebates are manufacturer-paid discounts, typically negotiated behind the scenes with insurers or pharmacy benefit managers (PBMs). These rebates are meant to lower the net cost of medications, but the full savings rarely make their way to employers or patients. And when it comes to high-cost infused medications billed under medical insurance (known as J-code drugs), things get even murkier.

Do rebates exist for these drugs? If so, who receives them? And why don’t most employers see the benefit?

What are pharmacy rebates anyway?

In the traditional pharmacy world, rebates are financial incentives paid by drug manufacturers to insurers or PBMs in exchange for preferred placement on a formulary or higher prescription volume. These rebates are issued after the drug is dispensed and can significantly reduce the net cost—at least on paper.

But here’s the catch: full rebates rarely flow back to employers. Instead, they’re often pocketed by the intermediaries who negotiate them with the employer only actually receiving a partial rebate. And for drugs billed through the medical benefit (like J-code infusions) the process is even more opaque.

Do rebates exist for J-code drugs?

Yes, rebates for medically billed J-code drugs do exist, but they're structured differently from traditional pharmacy rebates. Because these medications are billed through medical claims (under medical benefit, not pharmacy benefit), the negotiations typically occur directly between manufacturers and large medical groups, health systems, or insurers, often without involvement from a PBM.

Who actually gets these rebates?

Generally, rebates for medically billed drugs benefit:

• Large hospital systems or healthcare providers: These groups negotiate volume-based discounts directly with drug manufacturers, retaining the rebates themselves.
• Insurance carriers, large employers and third-party administrators (TPAs): Occasionally, insurers or TPAs negotiate rebates, but these rarely pass through directly to employers.

Smaller employers, individual businesses, and their employees rarely see these rebates reflected in their healthcare spending. Instead, they pay inflated costs, unaware of the hidden savings they should rightfully access.

The hidden costs of rebates

Rebates aren’t inherently bad, but the lack of transparency can significantly distort healthcare economics. Providers and hospitals might be incentivized to choose medications offering higher rebates rather than those most clinically appropriate or cost-effective for patients.

This dynamic leads to inflated overall healthcare costs, reduced clarity for employers around true drug costs and clinical decisions that could potentially be motivated by rebate profits rather than patient outcomes.

How much are we talking about?

Rebates on specialty infusion therapies and injectables can be substantial, often representing 10% to 30% (or more) of the drug’s list price. Given that many J-code medications cost tens or even hundreds of thousands of dollars annually per patient, these rebates represent substantial sums that could significantly offset healthcare costs, if they were transparent and accessible.

Why should employers care?

When rebates remain hidden, employers unknowingly absorb inflated drug prices through their healthcare spend. This directly impacts budgets, forcing difficult decisions about benefits or cost-sharing measures that negatively affect employees.

Transparency around J-code drug rebates ensures:

• Accurate budgeting and forecasting
• Fair and competitive drug pricing
• Improved employee satisfaction with healthcare benefits
• Greater trust between employers and healthcare providers

How Leap impacts rebates and your overall costs

Leap flips the traditional rebate model by offering fully transparent, pass-through pricing. Rather than benefiting middlemen, Leap ensures employers pay only the true cost of specialty medications:

• Eliminating Markups: Leap's model removes unnecessary provider markups and administrative fees.
• Direct Savings: Employers immediately realize cost reductions, seeing savings of up to 50% compared to traditional site-of-service arrangements.
• Improved Care Coordination: Beyond pricing transparency, Leap provides seamless care delivery, boosting adherence and patient satisfaction, and driving further cost-efficiencies.

In short, Leap ensures any financial benefit—rebates or otherwise—is transparently passed through, empowering employers to control specialty drug spend proactively.

Transparency in healthcare shouldn’t be a luxury. By shedding light on hidden rebates, Leap is helping employers regain control of their healthcare spend, ensure clinical integrity, and foster better patient outcomes.